Camille Sebaaly - Sunshine Biopharma CFO Secretary
| SBFMW Stock | USD 0.28 0.08 22.22% |
CFO
Camille Sebaaly is CFO Secretary of Sunshine Biopharma Warrant
| Age | 66 |
| Address | 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301 |
| Phone | 954-515-0810 |
| Web | https://sunshinebiopharma.com |
Camille Sebaaly Latest Insider Activity
Tracking and analyzing the buying and selling activities of Camille Sebaaly against Sunshine Biopharma stock is an integral part of due diligence when investing in Sunshine Biopharma. Camille Sebaaly insider activity provides valuable insight into whether Sunshine Biopharma is net buyers or sellers over its current business cycle. Note, Sunshine Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sunshine Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Camille Sebaaly over three months ago Acquisition by Camille Sebaaly of 30000 shares of Sunshine Biopharma at 0.7635 subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 14000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 26000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 |
Sunshine Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1798) %, meaning that it generated substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.16 in 2025. Return On Capital Employed is likely to climb to -0.19 in 2025. At this time, Sunshine Biopharma's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30.1 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (1.7 M).Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 |
Sunshine Biopharma Leadership Team
Elected by the shareholders, the Sunshine Biopharma's board of directors comprises two types of representatives: Sunshine Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sunshine. The board's role is to monitor Sunshine Biopharma's management team and ensure that shareholders' interests are well served. Sunshine Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sunshine Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Abderrazzak Merzouki, Chief Director | ||
| Camille Sebaaly, CFO Secretary | ||
| Steve Slilaty, President Chairman | ||
| Robert Ferreira, President Inc | ||
| Malek Chamoun, Chief Officer | ||
| Michel Roy, Chief Officer | ||
| Marc Beaudoin, Chief Officer |
Sunshine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sunshine Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Number Of Shares Shorted | 1.64 K | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 10.14 M | ||||
| EBITDA | (3.82 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 40.56 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.